The Joe Tippens Protocol (2026): Complete Step-by-Step Guide — Original Protocol, Dosage & Where to Buy
- Dr. Kimryn Rathmell
- 4 days ago
- 12 min read
In 2016, an Oklahoma businessman named Joe Tippens was given three months to live. He had been diagnosed with small-cell lung cancer that had spread throughout his entire body — to his neck, stomach, bladder, pancreas, and lungs. He was enrolled in a clinical trial for pembrolizumab (Keytruda), the revolutionary immunotherapy drug, but his doctors were not optimistic. Three months later, his PET scan showed no detectable cancer anywhere in his body.
Joe Tippens attributes a significant part of his recovery to Fenbendazole — a common veterinary deworming drug — combined with a handful of supplements, all taken alongside his immunotherapy treatment. He shared his story on his blog "My Cancer Story Rocks" in 2019. Within weeks, it had been read by people in over 60 countries. Cancer patients across the world — particularly those with late-stage or treatment-resistant cancers — began following what became known as the Joe Tippens Protocol.
As of January 2026, Joe Tippens is still alive and in remission — ten years out from his original terminal diagnosis. In February 2026, he appeared publicly at the Annie Appleseed Cancer Conference in West Palm Beach, Florida. In December 2025, he posted a video update on his blog. His story continues to inspire hundreds of thousands of people globally every year.
This complete 2026 guide covers the full story behind the Joe Tippens Protocol, the original protocol with exact dosages, the 2024–2026 updated version that adds Ivermectin and additional supplements, the scientific mechanisms behind each component, what the research actually shows, critical safety information including the hepatotoxicity warning, and how to buy pharmaceutical-grade Fenbendazole at the most affordable price in the USA with free shipping.
At TheMedicineKart, we stock Wormentel (Fenbendazole 500mg), Ivermectin (6mg to 40mg), and Febentel Plus (Fenbendazole 500mg + Ivermectin 25mg combined) — all sourced from WHO-GMP certified manufacturers, with USA-to-USA delivery and 50% off your first order using code MK50. Browse our full range at www.themedicinekart.com/anti-worm
The Story — Who Is Joe Tippens and What Happened?
Joe Tippens is an Oklahoma-based businessman who was diagnosed in 2016 with stage IV small-cell lung cancer — one of the most aggressive and treatment-resistant forms of cancer. The disease had metastasized extensively throughout his body: his neck, stomach, bladder, pancreas, and both lungs showed active cancer. His doctors gave him approximately three months to live.
At the time, Tippens was enrolled in a clinical trial for pembrolizumab (Keytruda) — an immune checkpoint inhibitor that was emerging as a breakthrough in lung cancer treatment. But he was not expected to be among those who responded. On the advice of an animal scientist friend who had observed Fenbendazole's effects on tumor growth in laboratory animals, Tippens began self-administering 222mg of Fenbendazole per day alongside his Keytruda treatment.
Three months later, at the first follow-up PET scan, radiologists found no detectable cancer anywhere in his body. He had achieved complete remission.
Tippens is quick to acknowledge that he cannot be certain whether the Fenbendazole, the pembrolizumab, or the combination of both produced his outcome. He also notes that he was one of only a handful of patients in the Keytruda trial who achieved such a dramatic response — while the majority did not. What he is certain of is that he added Fenbendazole to his regimen, and three months later he was cancer-free.
He shared his story publicly in 2019 through his blog "My Cancer Story Rocks" — which was read by people in over 60 countries within weeks of publication. A Google Trends analysis showed a dramatic spike in global searches for Fenbendazole immediately following the story's viral spread. Joe Tippens' story triggered a global wave of interest that shows no signs of slowing in 2026.
Confirmed 2026 status: As of January 2026, Joe Tippens is alive and in complete remission — 10 years after his original terminal diagnosis. He appeared at the Annie Appleseed Cancer Conference in West Palm Beach in February 2026 and posted a video update on his blog in December 2025. He reports continuing a maintenance version of the protocol.
The Original Joe Tippens Protocol — Exact Dosages
The original protocol that Joe Tippens followed and publicly documented consists of four components:
Component | Dose | Frequency | Schedule |
Fenbendazole | 222 mg | Once daily | 3 days on, 4 days off |
Bioavailable Curcumin | 600 mg | Once daily | 7 days a week |
CBD Oil (Full Spectrum) | 25 mg | Once daily | 7 days a week |
Vitamin E Succinate | 400–800 IU | Once daily | 7 days a week |
The original protocol requires Fenbendazole 222mg per day for three consecutive days, followed by four days off — then repeat. This cycling schedule was designed by Tippens to allow the liver resting periods, since Fenbendazole is metabolized extensively by the liver's CYP450 enzyme system (specifically CYP2C19 and CYP2J2).
Note on Vitamin E:
Joe Tippens has since removed Vitamin E Succinate from his protocol in the most recent updates posted on mycancerstory.rocks (last updated December 2025). The current official Tippens protocol now focuses on Fenbendazole, curcumin, CBD, and the Onco-Adjunct supplement pathways he developed under his UltraBotanica brand.
Important:
The 222mg dose referenced in Joe Tippens' protocol is the amount of Fenbendazole contained in 1 gram of Panacur C (a veterinary product). If using pharmaceutical-grade human Fenbendazole tablets such as Wormentel 500mg from TheMedicineKart, the equivalent dose is approximately half a tablet for the standard 222mg dose, or one full 500mg tablet for the more common intermediate doses now used in 2026 protocols.
The 2024–2026 Updated Joe Tippens Protocol
Since Joe Tippens first published his protocol, integrative oncology research — particularly the peer-reviewed paper published in the Journal of Orthomolecular Medicine in September 2024 co-authored by Dr. Paul Marik and Dr. William Makis — has significantly expanded the protocol. The updated 2026 version reflects five years of community experience, published case reports, and the addition of Ivermectin as a primary companion drug.
Component | Original (2019) | Updated 2026 Version | Notes |
Fenbendazole | 222 mg, 3 on / 4 off | 300–500 mg daily (or up to 1 g aggressive) | Pharmaceutical-grade Wormentel preferred |
Ivermectin | Not included | 25 mg, 6 days/week (up to 1 mg/kg/day) | Added based on 2024 JSOM publication |
Bioavailable Curcumin | 600 mg daily | 600 mg twice daily | Increased dose in updated protocols |
CBD Oil | 25 mg daily | 50–100 mg daily | Increased for aggressive cancers |
Vitamin E Succinate | 400–800 IU daily | Removed from current official protocol | Tippens removed this December 2025 |
Berberine | Not included | 500 mg daily | Added — glucose/sugar metabolism support |
Vitamin D3 | Not included | 5,000–10,000 IU daily | Added — immune modulation |
High-Dose Melatonin | Not included | 20–60 mg nightly (up to 100–180 mg) | Added — oncostatic + antioxidant effects |
Diet | Not specified | Low-sugar / ketogenic strongly recommended | Per 2026 AACR study on ultra-processed foods |
The 2024 Journal of Orthomolecular Medicine paper — "Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol" — represents the first peer-reviewed academic publication of an Ivermectin, Mebendazole, and Fenbendazole combination protocol, giving the updated Joe Tippens-derived protocols formal academic legitimacy for the first time.
Why Each Component? — The Science Behind the Protocol
Fenbendazole (the core agent):
Fenbendazole attacks cancer through multiple independent mechanisms simultaneously:
- Beta-tubulin binding — disrupts cell division (same mechanism as taxane chemotherapy)
- GLUT1 glucose transporter blockade — starves cancer cells of their primary fuel
- mTOR pathway suppression — reduces cancer cell growth and proliferation
- p53 reactivation — restores tumor suppressor function
- Wnt/beta-catenin pathway inhibition — relevant in colorectal and breast cancer
- Apoptosis induction — triggers programmed cancer cell death
- Ferroptosis induction — iron-dependent cell death pathway
- NLRP3 inflammasome activation — stimulates innate immune response
The multi-target nature of Fenbendazole's action — attacking division, glucose supply, growth signaling, and cell death simultaneously — makes it significantly harder for cancer cells to develop resistance through any single mutation than against a single-mechanism drug.
Ivermectin (the 2024–2026 addition):
Added to the updated protocol based on its complementary mechanisms:
- PD-L1 downregulation — unmasks cancer cells from the immune system
- Macrophage repolarization from tumor-protecting (M2) to tumor-killing (M1)
- PAK1 kinase inhibition — relevant in breast, colon, pancreatic cancer
- mTOR inhibition — synergistic with Fenbendazole
- Mitochondrial Complex I disruption — attacks cancer energy production
The scientific rationale for combining Ivermectin with Fenbendazole is that they target cancer through independent pathway clusters — structural/metabolic (Fenbendazole) and immune/signaling (Ivermectin). Febentel Plus (Fenbendazole 500mg + Ivermectin 25mg) from TheMedicineKart delivers both in one tablet.
Bioavailable Curcumin:
Curcumin (the active compound in turmeric) has been shown in multiple laboratory studies to increase healthy p53 levels, reduce NF-kB inflammatory signaling, and potentially synergise with Fenbendazole's p53 reactivation mechanism. Standard turmeric supplements have very low bioavailability — the protocol specifically calls for bioavailable or enhanced-absorption curcumin formulations (such as Theracurmin, Longvida, or curcumin with piperine/black pepper extract).
CBD Oil:
Full-spectrum CBD has been studied for potential tumor growth modulation effects and symptom management (pain, nausea, anxiety, sleep). Joe Tippens specified full-spectrum, high-purity broad-spectrum CBD at 25mg daily in the original protocol.
Berberine (2026 addition):
Berberine — a plant alkaloid — inhibits the same AMPK pathway as Metformin and has been shown to restrict glucose uptake in cancer cells, complementing Fenbendazole's GLUT1 blockade. Many 2026 protocol users describe it as "the plant-based Metformin."
High-dose Melatonin (2026 addition):
High-dose melatonin (above 10mg) has a growing body of preclinical evidence suggesting direct oncostatic (tumor-inhibiting) effects at these pharmacological doses — distinct from its standard sleep-regulating role at 0.5–3mg. Doses of 20–180mg nightly are now incorporated in advanced Tippens-derived protocols.
Diet (2026 emphasis):
A 2026 study published by the American Association for Cancer Research linked ultra-processed food consumption to significantly reduced survival after cancer diagnosis. Sugar and starch consumption is now explicitly identified as working against the protocol's mechanisms — particularly Fenbendazole and Berberine's glucose metabolism disruption. The updated Joe Tippens Protocol now strongly recommends a low-sugar or ketogenic diet as the dietary foundation.
Dosage Guide — Which Fenbendazole Strength Do I Need?
Protocol Level | Cancer Situation | Fenbendazole Dose | Ivermectin Dose | Schedule |
Maintenance / Prevention | Post-remission; low-risk | 222 mg | Optional | 3 days on / 4 days off |
Standard | Early-stage; slow-growing | 222–300 mg daily | 12–25 mg, 6 days/week | 3 on / 4 off or daily |
Intermediate | Moderate; stage 3 | 444–500 mg daily | 25 mg, 6 days/week | Daily with fatty meal |
Aggressive | Stage 4; rapidly progressing | 500 mg–1,000 mg daily | 1 mg/kg daily | Daily continuous |
Turbo Cancer | Treatment-resistant; rapidly worsening | Up to 1,500 mg daily | 1.5–2 mg/kg daily | Daily — medical supervision required |
TheMedicineKart Fenbendazole options by protocol level:
- Wormentel 500mg — covers standard, intermediate, and aggressive protocol doses
- For 222mg dose: split one 500mg tablet in half (score line present on most formulations)
- Febentel Plus (Fenbendazole 500mg + Ivermectin 25mg) — covers intermediate protocol in one tablet
- Standalone Ivermectin available separately in 6mg, 12mg, 15mg, 20mg, 40mg for weight-adjusted dosing
Always take Fenbendazole and Ivermectin with a high-fat meal. Both are lipophilic (fat-soluble) drugs and their oral bioavailability increases dramatically — up to 5x — when taken with dietary fat such as whole milk, avocado, olive oil, or full-fat yogurt. This single step significantly improves the amount of active drug that reaches the bloodstream.
What the Research Shows — Honest 2026 Assessment
Joe Tippens' story is compelling, but an honest evaluation of the research in 2026 requires distinguishing between what is proven and what is promising:
What the evidence supports:
- Fenbendazole demonstrates multiple anticancer mechanisms in laboratory (in vitro) and animal (in vivo) studies — microtubule disruption, glucose blockade, apoptosis, p53 reactivation — published in multiple peer-reviewed journals including Anticancer Research and Scientific Reports
- A 2021 case series documented three patients with genitourinary malignancies achieving complete responses with Fenbendazole, either alone or combined with standard therapies
- A 2025 case series in Case Reports in Oncology documented patients with Stage IV breast cancer and Stage IV melanoma achieving complete remission with daily 222mg Fenbendazole use
- A 2022 retrospective PLoS ONE study analyzed the experiences of patients using the Tippens protocol and documented their perceptions and outcomes
- A 2026 World Journal of Clinical Cases report documented severe hepatotoxicity in a patient who switched from the 3-on/4-off cycle to a continuous daily schedule — reinforcing the importance of liver monitoring
- The Journal of Orthomolecular Medicine (September 2024) published the first peer-reviewed combined Ivermectin/Mebendazole/Fenbendazole protocol — co-authored by Dr. Paul Marik and Dr. William Makis
What the evidence does NOT yet show:
- No Phase III randomized controlled trial has confirmed Fenbendazole as an effective cancer treatment in humans
- Joe Tippens was concurrently enrolled in a clinical trial for pembrolizumab (Keytruda) — an immunotherapy drug now known to produce complete responses in a subset of lung cancer patients — which cannot be excluded as the primary driver of his remission
- The FDA has not approved Fenbendazole for any human indication, including cancer
- A SciQST 2025 review reported Fenbendazole may, under specific experimental conditions, promote tumor growth — reinforcing the necessity of regular imaging and medical supervision
The honest assessment in 2026: Fenbendazole has a scientifically plausible anticancer mechanism, a large and growing body of anecdotal signal data, an emerging published case report literature, and a favorable safety profile at standard doses. It does not yet have the large-scale randomized controlled trial data needed to constitute proof of efficacy as a cancer treatment. It is most responsibly used as part of a comprehensive treatment plan that includes conventional oncology care — not as a replacement for it.
Critical Safety Information
The most important safety rule: Liver monitoring is mandatory.
A 2026 report in the World Journal of Clinical Cases documented a patient who developed severe hepatotoxicity within one week of switching from the cycled 3-on/4-off schedule to a continuous daily schedule. Fenbendazole is metabolized extensively by the liver through the CYP2C19 and CYP2J2 enzyme pathways. Without adequate resting periods, the liver can become overwhelmed — particularly at doses above 500mg daily.
Mandatory monitoring protocol for anyone following the Joe Tippens Protocol:
- Baseline before starting: Complete liver function panel (AST, ALT, bilirubin, alkaline phosphatase), CBC, kidney function (creatinine, eGFR)
- Every 4 weeks during active use: Repeat liver function panel + CBC
- If AST or ALT rises above 3x the upper limit of normal: Reduce dose and consult your physician immediately
- If AST or ALT rises above 5x the upper limit of normal: Stop Fenbendazole completely and seek urgent medical evaluation
Who should use extra caution or consult a physician first:
- Anyone with pre-existing liver conditions
- Anyone currently on chemotherapy or immunotherapy — inform your oncologist before adding Fenbendazole
- Patients with Loa loa (loiasis) — high microfilariae levels combined with Ivermectin component can cause serious neurological reactions
- Pregnant or breastfeeding women — insufficient safety data; not recommended
- Anyone on warfarin or other CYP450-metabolized medications — potential interactions
The Joe Tippens Protocol should never replace conventional oncology treatment. It is most responsibly pursued as a complementary approach, discussed openly with your oncology team, with regular monitoring in place.
Where to Buy Pharmaceutical-Grade Fenbendazole in the USA
This is a critical consideration in 2026. Following the FDA's 2025 crackdown on compounding pharmacies, the compounded Fenbendazole market that supplied many US patients during 2022–2024 is now largely restricted. Veterinary products like Panacur C and Safe-Guard — while containing Fenbendazole — are formulated for animals and vary in purity, concentration, and inactive ingredients.
TheMedicineKart is one of the most reliable compliant sources for pharmaceutical-grade human Fenbendazole in the USA in 2026:
Product | Strength | For Protocol Level | Price with MK50 |
Wormentel (Fenbendazole) | 500 mg tablet | Standard to aggressive | As low as $0.50–$1.50/pill |
Febentel Plus | 500 mg FBZ + 25 mg IVM | Intermediate to aggressive (combined) | As low as $1–$2/tablet |
Ivermectin | 6 mg, 12 mg, 15 mg, 20 mg, 40 mg | Standard to turbo (Makis protocol) | As low as $0.50–$1/pill |
All TheMedicineKart products are:
- Sourced from WHO-GMP certified manufacturers (Centurion Laboratories, Mankind Pharma)
- Pharmaceutical-grade human tablets — not veterinary formulations
- Quality-verified before dispatch
- Delivered USA-to-USA in 4 business days in fully discreet plain packaging
- 50% off first order with code MK50
- Free shipping on orders above $199
Browse the full range at www.themedicinekart.com/anti-worm
Frequently Asked Questions
Is Joe Tippens still alive in 2026?
Yes — confirmed. As of January 2026, Joe Tippens is alive and in complete remission, marking ten years since his original terminal cancer diagnosis. He appeared at the Annie Appleseed Cancer Conference in West Palm Beach in February 2026 and posted a video update on his blog in December 2025. He reports continuing a maintenance version of the protocol.
What is the exact Joe Tippens Protocol dosage for Fenbendazole?
The original Joe Tippens Protocol calls for 222mg of Fenbendazole per day, taken for 3 consecutive days followed by 4 days off — the "3 days on, 4 days off" cycling schedule. This was originally achieved using 1 gram of Panacur C (a veterinary product containing 222mg of Fenbendazole per gram). For pharmaceutical-grade human Wormentel 500mg tablets from TheMedicineKart, half a tablet delivers approximately 250mg — close to the standard dose. Updated 2026 protocols commonly use 300–500mg daily. For aggressive cancers, doses of up to 1,000mg daily are documented in case reports.
Does Joe Tippens attribute his remission entirely to Fenbendazole?
No — Joe Tippens has consistently acknowledged that he was simultaneously enrolled in a clinical trial for pembrolizumab (Keytruda), the immune checkpoint inhibitor immunotherapy. He cannot be certain whether the Fenbendazole, the Keytruda, or the combination of both produced his complete remission. He was also reportedly the only patient among 1,100 trial participants to achieve a complete response, which raises the question of whether Fenbendazole provided additive or synergistic benefit with the immunotherapy. This is precisely the question that the ICONIC clinical trial (NCT07487805) — combining Ivermectin with checkpoint inhibitors — is now trying to answer formally.
Can I take the Joe Tippens Protocol alongside chemotherapy or immunotherapy?
Many patients in the case report literature have used the protocol alongside conventional treatment. However, some components — particularly curcumin and CBD — have antioxidant properties that may theoretically interfere with certain chemotherapy mechanisms, and Fenbendazole uses the same CYP450 enzyme pathways as several chemotherapy drugs, creating potential interaction risk. It is absolutely essential to inform your oncologist before adding any component of the Joe Tippens Protocol to an existing cancer treatment regimen. Do not self-administer without medical supervision.
Where can I buy pharmaceutical-grade Fenbendazole for the Joe Tippens Protocol in the USA in 2026?
TheMedicineKart stocks Wormentel (Fenbendazole 500mg), Febentel Plus (Fenbendazole 500mg + Ivermectin 25mg), and standalone Ivermectin — all sourced from WHO-GMP certified pharmaceutical manufacturers, in human pharmaceutical-grade formulations, not veterinary products. Use code MK50 for 50% off at www.themedicinekart.com/anti-worm. Free shipping on orders above $199. USA-to-USA delivery in 4 business days in discreet plain packaging.